TY - JOUR T1 - Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death in high risk atherothrombosis JF - Evidence Based Medicine JO - Evid Based Med SP - 143 LP - 143 DO - 10.1136/ebm.11.5.143 VL - 11 IS - 5 A2 - , Y1 - 2006/10/01 UR - http://ebm.bmj.com/content/11/5/143.abstract N2 - Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706–17.OpenUrlCrossRefPubMedWeb of Science 
 
 Q In patients with high risk atherothrombosis, is long term treatment with clopidogrel plus aspirin more effective than aspirin alone for reducing cardiovascular (CV) events? Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ IM/Ambulatory care ★★★★★★☆ Internal medicine ★★★★★★☆ Neurology ★★★★★★☆ Cardiology ★★★★★★☆ Design: randomised placebo controlled trial (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilisation, Management, and Avoidance [CHARISMA]). Allocation: concealed.* Blinding: blinded {clinicians, patients, data collectors, outcome assessors, data analysts, and data safety and monitoring committee}†.* Follow up period: median 28 months. Setting: 768 sites in 32 countries. Patients: 15 603 patients ⩾45 years of age (median age 64 y, 70% men, 80% white) who had multiple atherothrombotic risk factors (type 1 or 2 diabetes, diabetic nephropathy, ankle brachial index <0.9, asymptomatic carotid stenosis ⩾70% of luminal diameter, ⩾1 carotid plaque, systolic blood pressure ⩾150 … ER -